鳖龙软肝汤联合经肝动脉化疗栓塞术治疗HBV相关原发性肝癌临床观察

伍玉南; 张冬; 孙克伟

doi:10.3969/j.issn.1001-5256.2017.11.020

鳖龙软肝汤联合经肝动脉化疗栓塞术治疗HBV相关原发性肝癌临床观察

DOI: 10.3969/j.issn.1001-5256.2017.11.020

1. 湖南中医药大学第一附属医院肝病研究所
2. 湖南中医药大学研究生院

基金项目:

国家自然科学基金青年科学基金项目(8150151150)；

详细信息

中图分类号: R512.62;R735.7
计量
- 文章访问数: 280
- HTML全文浏览量: 12
- PDF下载量: 159
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-05
- 出版日期: 2017-11-20

Clinical effect of Bielong Ruangan decoction combined with transcatheter arterial chemoembolization in treatment of hepatitis B virus-related primary liver cancer

The First Affiliated Hospital of Hunan University of Chinese Medicine, Institute of Hepatology

Research funding:

摘要

摘要: 目的分别观察接受鳖龙软肝汤联合经肝动脉化疗栓塞术（TACE）治疗和单纯TACE治疗的HBV相关原发性肝癌患者临床疗效,比较2种方法疗效的差异。方法选取2014年3月-2016年3月在湖南中医药大学第一附属医院肝病中心住院治疗的HBV相关原发性肝癌患者,随机分为试验组和对照组。试验组给予鳖龙软肝汤联合TACE治疗,对照组给予单一TACE治疗。观察2组治疗后的近期疗效、中医症候积分及血清AFP下降程度、TACE术后综合征的发生率及1年生存率。计量资料2组间比较采用t检验;计数资料2组间比较采用χ2检验,等级资料组间比较Ridit分析;并用Kaplan-Meier法计算生存率,绘制生存曲线,采用log-rank检验对2组生存率进行比较。结果研究组瘤体疗效客观反应率为77.4%,对照组56.4%,差异有统计学意义（χ2=9.898,P=0.020）;中医症候积分下降水平两组比较,差异有统计学意义;两组治疗前后血清AFP下降程度比较,差异具有统计学意义（t=2.194,P=0.030）;TACE术后2组栓塞综合征的发生率比较,研究组发热、恶心、呕吐、纳...
- 肝肿瘤 /
- 肝炎病毒,乙型 /
- 化学栓塞,治疗性 /
- 鳖龙软肝汤
Abstract: Objective To investigate the clinical effect of Bielong Ruangan decoction combined with transcatheter arterial chemoembolization (TACE) versus TACE alone in the treatment of hepatitis B virus (HBV) -related primary liver cancer.Methods The patients with HBV-related primary liver cancer who were hospitalized in Liver Research Center in The First Affiliated Hospital of Hunan University of Chinese Medicine from March 2014 to March 2016 were enrolled and randomly divided into study group and control group.The patients in the study group were treated with Bielong Ruangan decoction combined with TACE, and those in the control group were treated with TACE alone.The two groups were observed in terms of short-term therapeutic effect, traditional Chinese medicine (TCM) syndrome score, reduction in serum alpha-fetoprotein (AFP) , incidence rate of post-TACE syndrome, and 1-year survival rate.The t-test was used for comparison of continuous data between groups;the chi-square test was used for comparison of categorical data between groups;the ridit analysis was used for comparison of ranked data between groups;the Kaplan-Meier method was used to calculate survival rate and plot survival curves;the log-rank test was used to compare survival rates between groups.Results There were significant differences between the study group and the control group in objective tumor response rate (77.4% vs 56.4%, χ2=9.898, P=0.020) and reductions in TCM syndrome score and serum AFP level (t=2.194, P=0.030) .As for the incidence rate of embolism syndrome after TACE, the study group had significantly lower incidence rates of pyrexia, nausea, vomiting, and poor appetite than the control group (all P<0.05) .The study group had significantly higher quality of life and physical scores than the control group (t=-3.893 and-6.187, both P<0.001) .There was also a significant difference in 1-year survival rate between the study group and the control group [77.4% (48/62) vs 63.6% (35/55) , χ2=4.228, P=0.040].Conclusion In patients with HBV-related primary liver cancer, Bielong Ruangan decoction combined with TACE can improve their short-term clinical outcome and quality of life.
- liver neoplasms /
- hepatitis B virus /
- chemoembolization, therapeutic /
- Bielong Ruangan decoction

HTML全文

参考文献(21)

[1]AN LM, YU SQ.Clinical studies on relationship between primary liver cancer and hepatitis B virus marker[J].Clin Med Eng, 2009, 16 (6) :14-15. (in Chinese) 安良敏, 余素琼.原发性肝癌与乙肝病毒标志物系临床研究[J].临床医学工程, 2009, 16 (6) :14-15.

[2]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :1-16. (in Chinese) 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :1-16.

[4]Study Group of Interventional Radiology, Editorial Board of Chinese Journal of Radiology, Chinese Medical Association.Regulations on standardization of interventional treatment of liver cancer[J].Chin JRadiol, 2011, 35 (12) :887-891. (in Chinese) 中华医学会中华放射学杂志编委会介入放射学组.肝癌介入治疗规范化条例 (草案) [J].中华放射学杂志, 2011, 35 (12) :887-891.

[5]ZHENG XY.Guidelines for clinical research of Chinese medicine (New Drug) [M].Beijing:China Medical Science Press, 2002:210-212. (in Chinese) 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002:210-212.

[6] HAO J, CHEN WQ.Chinese cancer registry annual report (2012) [M].Beijing:Military Medical Science Press, 2012. (in Chinese) 郝捷, 陈万青.中国肿瘤登记年报 (2012) [M].北京:军事医学科学出版社, 2012.

[7]DAI CL, ZHAO Y.Comprehensive treatment for primary liver cancer[J].Chin J Bases Clin General Surg, 2014, 21 (2) :133-137. (in Chinese) 戴朝六, 赵阳.原发性肝癌的综合治疗[J].中国普外基础与临床杂志, 2014, 21 (2) :133-137.

[8]XU T, ZHANG T, ZHOU JJ, et al.Efficacy of CT guided radioactive 125I seed intratumoral implantation combined with TACE in treatment of liver cancer[J].Chin J Med Offic, 2015, 43 (3) :237-239. (in Chinese) 许涛, 张涛, 周进军, 等.CT导向下放射性125I粒子瘤内植入联合肝动脉化疗栓塞术治疗肝癌的疗效[J].临床军医杂志, 2015, 43 (3) :237-239.

[9]CHU ZZ, CHEN LH, FENG JH, et al.Advantage and treatment of traditional Chinese medicine in treating primary hepatic carcinoma[J].China J Chin Med, 2013, 28 (185) :1446-1448. (in Chinese) 储真真, 陈立宏, 冯久桓, 等.中医药治疗原发性肝癌研究进展[J].中医学报, 2013, 28 (185) :1446-1448.

[10]LUO D, YE HL.Current situation and prospects of experimental researches on treatment of hepatoma using traditional Chinese herbs[J].World Chin J Dig, 2008, 16 (26) :2964-2968. (in Chinese) 骆丹, 叶丽红.中药治疗肝癌在实验研究领域的发展现状及趋势[J].世界华人消化杂志, 2008, 16 (26) :2964-2968.

[11]HAN ZY, HAN Z, ZHU JF.Traditional Chinese medicine treatment of primary liver cancer[J].J Changchun Univ Chin Med, 2016, 32 (2) :426-429. (in Chinese) 韩中颖, 韩政, 祝峻峰.中医药治疗原发性肝癌临床研究进展[J].长春中医药大学学报, 2016, 32 (2) :426-429.

[12]YE LH, CHENG HB, ZHANG YH, et al.Principle of treatment and therapies for primary liver cancer based on traditional Chinese medicine[J].J Nangjing Univ Tradit Chin Med, 2010, 26 (1) :10-13. (in Chinese) 叶丽红, 程海波, 章永红, 等.原发性肝癌的中医治则与治法探讨[J].南京中医药大学学报, 2010, 26 (1) :10-13.

[13]GENG T, XIE ML, PENG SP.Effect of peach seed extract against myocardial ischemia in rats[J].Suzhou Univ J Med Sci, 2005, 25 (2) :238-240. (in Chinese) 耿涛, 谢梅林, 彭少平.桃仁提取物抗大鼠心肌缺血作用的研究[J].苏州大学学报:医学版, 2005, 25 (2) :238-240.

[14]LIU Y, XU T.Effect of peach seeds protein on antigen presentation function of dendritic cells[J].Liaoning J Tradit Chin Med, 2007, 34 (12) :1810-1811. (in Chinese) 刘英, 许铁.桃仁蛋白对树突细胞抗原递呈功能的影响[J].辽宁中医杂志, 2007, 34 (12) :1810-1811.

[15]LYU YS, WANG YX.Effect of total protein in peach seed on the levels of interleukin-2 and interleukin-4 in tumor-bearing mice[J].Inf Tradit Chin Med, 2004, 21 (4) :60-61. (in Chinese) 吕跃山, 王雅贤.桃仁总蛋白对荷瘤鼠IL-2、IL-4水平的影响[J].中医药信息, 2004, 21 (4) :60-61.

[16]XU HY, YUN CX, WANG YX.The effects of PSP on the subset of T cell and apoptosis of the tumor-bearing mice[J].Qigihar Med J, 2004, 25 (5) :485-487. (in Chinese) 许惠玉, 运晨霞, 王雅贤.桃仁总蛋白对荷瘤鼠T淋巴细胞亚群及细胞凋亡的影响[J].齐齐哈尔医学院学报, 2004, 25 (5) :485-487.

[17]TANG Y, LI XH.Inhibitory effects of zedoray rhizome abstracts on hepatic cell line Hep G2 and their mechanisms[J].Chin Pharmacol Bull, 2007, 23 (6) :790-794. (in Chinese) 唐渊, 李晓辉.莪术提取物对肝癌细胞系Hep G2的抗癌作用及机制研究[J].中国药理学通报, 2007, 23 (6) :790-794

[18]HE Y, HU ZF, LI P, et al.Experimental study of saikosaponin-d (SSd) on lipid peroxidation of hepatic fibrosis on rat[J].China JChin Mater Med, 2005, 33 (8) :915-919. (in Chinese) 何燕, 胡志峰, 李平, 等.柴胡皂苷d抗肝纤维化大鼠脂质过氧化作用的研究[J].中国中药杂志, 2005, 33 (8) :915-919.

[19]WANG H, WEI W, YUE L, et al.Protective effect of total glucosides of paeony on immunological liver injury in mice induced by bacillus calmette-guerin plus lipopolysaccharide[J].Chin Pharmacol Bull, 2004, 20 (8) :875-878. (in Chinese) 王华, 魏伟, 岳莉, 等.白芍总苷对卡介苗加脂多糖引起的小鼠免疫性肝损伤的保护作用[J].中国药理学通报, 2004, 20 (8) :875-878.

[20]ZHANG QY, ZHANG ZK, JIN SQ.Advances in modern clinical application of Biejia decoction pills and experimental studies[J].JHebei Tradit Chin Med Pharmacol, 2006, 21 (1) :35-36. (in Chinese) 张秋英, 张再康, 金淑琴.鳖甲煎丸的现代临床应用和实验研究进展[J].河北中医药学报, 2006, 21 (1) :35-36.

[21]LEI JS, GUO JS.Effect of Bielong Ruangan tablets on live fibrosis in experimental rats:a pathological study[J].J Hunan Coll Tradit Chin Med, 2000, 20 (1) :22-23. (in Chinese) 雷久士, 郭建生.鳖龙软肝片对实验大鼠肝纤维化的病理研究[J].湖南中医学院学报, 2000, 20 (1) :22-23.

施引文献

资源附件(0)

访问统计